Merck
  • Home
  • Search Results
  • MicroRNA-654-5p suppresses ovarian cancer development impacting on MYC, WNT and AKT pathways.

MicroRNA-654-5p suppresses ovarian cancer development impacting on MYC, WNT and AKT pathways.

Oncogene (2019-07-07)
Blanca Majem, Alfonso Parrilla, Carlos Jiménez, Leticia Suárez-Cabrera, Marta Barber, Andrea Marín, Josep Castellví, Gabriel Tamayo, Gema Moreno-Bueno, Jordi Ponce, Xavier Matias-Guiu, Francesc Alameda, Ignacio Romero, José Luis Sánchez, Asunción Pérez-Benavente, Sebastián Moran, Manel Esteller, Jaume Reventós, Marina Rigau, Antonio Gil-Moreno, Miguel F Segura, Anna Santamaría
ABSTRACT

Ovarian cancer is the most lethal gynecological malignancy due to the silent nature on its early onset and the rapid acquisition of drug resistance. Histologically heterogeneous, it includes several subtypes with different mutational landscapes, hampering the development of effective targeted therapies. Non-coding RNAs are emerging as potential new therapeutic targets in cancer. To search for a microRNA signature related to ovarian carcinomas and study its potential as effective targeted therapy, we examined the expression of 768 miRNA in a large collection of tumor samples and found miR-654-5p to be infraexpressed in ovarian serous carcinomas, the most common and aggressive type. Restoration of miR-654-5p levels reduced tumor cell viability in vitro and in vivo and impaired sphere formation capacity and viability of ovarian cancer patient-derived ascitic cells ex vivo. CDCP1 and PLAGL2 oncogenes were found to be the most relevant direct miR-654-5p targets and both genes convey in a molecular signature associated with key cancer pathways relevant to ovarian tumorigenesis, such as MYC, WNT and AKT pathways. Together, we unveiled the tumor suppressor function of miR-654-5p, suggesting that its restoration or co-targeting of CDCP1 and PLAGL2 may be an effective therapeutic approach for ovarian cancer.